104 related articles for article (PubMed ID: 20639123)
41. Immunotherapy of hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):345-53. PubMed ID: 20528121
[TBL] [Abstract][Full Text] [Related]
42. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
43. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
Brostjan C; Bayer A; Zommer A; Gornikiewicz A; Roka S; Benkö T; Yaghubian R; Jakesz R; Steger G; Gnant M; Friedl J; Stift A
Cancer; 2003 Nov; 98(10):2291-301. PubMed ID: 14601101
[TBL] [Abstract][Full Text] [Related]
44. [Therapy for malignancies and inflammatory disorders by modulating human dendritic cell functions].
Kadowaki N; Kitawaki T; Hirai M
Rinsho Ketsueki; 2011 Jul; 52(7):497-504. PubMed ID: 21821981
[No Abstract] [Full Text] [Related]
45. [Dendritic cells--strong candidates for immunotherapy].
Lund-Johansen F; Olweus J
Tidsskr Nor Laegeforen; 1999 Jun; 119(17):2510-4. PubMed ID: 10425906
[TBL] [Abstract][Full Text] [Related]
46. On probabilistic certification of combined cancer therapies using strongly uncertain models.
Alamir M
J Theor Biol; 2015 Nov; 384():59-69. PubMed ID: 26300070
[TBL] [Abstract][Full Text] [Related]
47. Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors.
Dolcetti R; López-Soto A; Dal Col J
Front Immunol; 2020; 11():507. PubMed ID: 32296426
[No Abstract] [Full Text] [Related]
48. A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy.
Robertson-Tessi M; El-Kareh A; Goriely A
J Theor Biol; 2015 Sep; 380():569-84. PubMed ID: 26087282
[TBL] [Abstract][Full Text] [Related]
49. Fine-tuning anti-tumor immunotherapies via stochastic simulations.
Caravagna G; Barbuti R; d'Onofrio A
BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S8. PubMed ID: 22536975
[TBL] [Abstract][Full Text] [Related]
50. The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?
Krishchenko AP; Starkov KE
Math Biosci Eng; 2018 Oct; 15(5):1243-1254. PubMed ID: 30380309
[TBL] [Abstract][Full Text] [Related]
51. Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.
Konstorum A; Vella AT; Adler AJ; Laubenbacher RC
J R Soc Interface; 2017 Jun; 14(131):. PubMed ID: 28659410
[TBL] [Abstract][Full Text] [Related]
52. On the global dynamics of a model for tumor immunotherapy.
Kirschner D; Tsygvintsev A
Math Biosci Eng; 2009 Jul; 6(3):573-83. PubMed ID: 19566127
[TBL] [Abstract][Full Text] [Related]
53. [Immunotherapy for hematological neoplasms].
Yasukawa M
Rinsho Ketsueki; 2012 Oct; 53(10):1759-67. PubMed ID: 23037749
[No Abstract] [Full Text] [Related]
54. A switching control law approach for cancer immunotherapy of an evolutionary tumor growth model.
Doban AI; Lazar M
Math Biosci; 2017 Feb; 284():40-50. PubMed ID: 27665680
[TBL] [Abstract][Full Text] [Related]
55. A model of dendritic cell therapy for melanoma.
Depillis L; Gallegos A; Radunskaya A
Front Oncol; 2013; 3():56. PubMed ID: 23516248
[TBL] [Abstract][Full Text] [Related]
56. Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment.
Atsou K; Khou S; Anjuère F; Braud VM; Goudon T
Front Oncol; 2022; 12():878827. PubMed ID: 35832538
[TBL] [Abstract][Full Text] [Related]
57. Mathematical modeling of cancer immunotherapy for personalized clinical translation.
Butner JD; Dogra P; Chung C; Pasqualini R; Arap W; Lowengrub J; Cristini V; Wang Z
Nat Comput Sci; 2022 Dec; 2(12):785-796. PubMed ID: 38126024
[TBL] [Abstract][Full Text] [Related]
58. Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy.
Kiran KL; Lakshminarayanan S
Biosystems; 2010 Aug; 101(2):117-26. PubMed ID: 20639123
[TBL] [Abstract][Full Text] [Related]
59. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
Castiglione F; Piccoli B
Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
[TBL] [Abstract][Full Text] [Related]
60. Determination of the optimal therapeutic protocols in cancer immunotherapy.
Cappuccio A; Castiglione F; Piccoli B
Math Biosci; 2007 Sep; 209(1):1-13. PubMed ID: 17416392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
